Response of ironweed and buckbrush to herbicides and to herbicides in combination with mowing, nitrogen fertilizer, and surfactants

Cooperating agency: Missouri Agricultural Experiment Station.

The state of the merger.

Mode of access: Internet.

A proposal for five-branch merger by the Joint study group on five-branch merger, Institute of Industrial Relations, University of California [and] New York State School of Industrial and Labor Relations, Cornell University.

Mimeographed.

The railroad merger problem. Report together with individual views of the Subcommittee on Antitrust and Monopoly of the Committee on the Judiciary, United States Senate pursuant to S. Res. 258, Eighty-seventh Congress, as extended providing for a study of the antitrust laws of the United States, and their administration, interpretation and effect.

At head of title: 88th Cong., 1st sess. Committee print.

Basic skills and employment and training programs : can the combination benefit employers, youth and community institutions? /

Includes bibliographical references (p. [8]).

Combination in the anthracite industry : pressure on the consumer and the wage earner of concentration of control of Anthracite reserves, production, transportation and distribution of anthracite coal /

At head of title: Before the United States Anthracite Coal Commission.

Uber Combination von Blatternschutzimpfung, Masern und multipler embolischer Gangran der Haut und Schleimhaute, zugleich ein Beitrag zur Frage der generalisirten Vaccine.

Mode of access: Internet.

Organ-stops and their artistic registration; names, forms, construction, tonalities, and offices in scientific combination,

Mode of access: Internet.

Development and testing of an airbag and energy absorbing lap belt combination restraint system: final report.

"Contract no. FH-11-6962."

Responses to a merger: The effects of premerger group status and integration pattern

Adopting a social identity perspective, the research was designed to examine the interplay between premerger group status and integration pattern in the prediction of responses to a merger. The research employed a 2 (status: high versus low) x 3 (integration pattern: assimilation versus integrational equality versus transformation) between-participants factorial design. We predicted that integration pattern and group status would interact such that the responses of the members of high status group would be most positive under conditions of an assimilation pattern, whereas members of low status groups were expected to favour an integration-equality pattern. After working on a task in small groups, group status was manipulated and the groups worked on a second task. The merger was then announced and the integration pattern was manipulated (e.g., in terms of the logo, location, and decision rules). The main dependent variables were assessed after the merged groups had worked together on a third task. As expected, there was evidence that the effects of group status on responses to the merger were moderated by integration pattern. Field data also indicated that both premerger status and perceived integration pattern influenced employee responses to an organisational merger.

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C

BACKGROUND: Sustained virological response (SVR) is the primary objective in the treatment of chronic hepatitis C (CHC). Results from a recent clinical trial of patients with previously untreated CHC demonstrate that the combination of peginterferon alpha-2a and ribavirin produces a greater SVR than interferon alpha-2b and ribavirin combination therapy. However, the cost-effectiveness of peginterferon alpha-2a plus ribavirin in the U.S. setting has not been investigated. METHODS: A Markov model was developed to investigate cost-effectiveness in patients with CHC using genotype to guide treatment duration. SVR and disease progression parameters were derived from the clinical trials and epidemiologic studies. The impact of treatment on life expectancy and costs were projected for a lifetime. Patients who had an SVR were assumed to remain virus-free for the rest of their lives. In genotype 1 patients, the SVRs were 46% for peginterferon alpha-2a plus ribavirin and 36% for interferon alpha-2b plus ribavirin. In genotype 2/3 patients, the SVRs were 76% for peginterferon alpha-2a plus ribavirin and 61% for interferon alpha-2b plus ribavirin. Quality of life and costs were based on estimates from the literature. All costs were based on published U.S. medical care costs and were adjusted to 2003 U.S. dollars. Costs and benefits beyond the first year were discounted at 3%. RESULTS: In genotype 1, peginterferon alpha-2a plus ribavirin increases quality-adjusted life expectancy (QALY) by 0.70 yr compared to interferon alpha-2b plus ribavirin, producing a cost-effectiveness ratio of $2,600 per QALY gained. In genotype 2/3 patients, peginterferon alpha-2a plus ribavirin increases QALY by 1.05 yr in comparison to interferon alpha-2b plus ribavirin. Peginterferon alpha-2a combination therapy in patients with HCV genotype 2 or 3 is dominant (more effective and cost saving) compared to interferon alpha-2b plus ribavirin. Results weighted by genotype prevalence (75% genotype 1; 25% genotype 2 or 3) also show that peginterferon alpha-2a plus ribavirin is dominant. Peginterferon alpha-2a and ribavirin remained cost-effective (below $16,500 per QALY gained) under sensitivity analyses on key clinical and cost parameters. CONCLUSION: Peginterferon alpha-2a in combination with ribavirin with duration of therapy based on genotype, is cost-effective compared with conventional interferon alpha-2b in combination with ribavirin when given to treatment-naive adults with CHC.

The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C

Background/Aims: Peginterferon alfa-2a plus ribavirin improves sustained virological responses compared with interferon alfa-2b and ribavirin, or peginterferon alfa-2a alone in chronic hepatitis C. We examined the impact of these treatments on health related quality of life (HRQOL). Methods: Patients (n = 1121) were randomized to peginterferon alfa-2a weekly plus ribavirin or placebo, or interferon alfa-2b thrice weekly plus ribavirin. HRQOL was assessed with the SF-36 Health Survey and Fatigue Severity Scale (FSS). Results: Patients receiving peginterferon alfa-2a plus ribavirin reported better HRQOL than those receiving interferon alfa-2b plus ribavirin. These differences were statistically significant for three SF-36 domains and both FSS scores (p < = 0.05). Patients receiving peginterferon alfa-2a plus placebo had the least impairment; adding ribavirin significantly decreased five domains of the SF-36 and both FSS scores. Sustained virological response was associated with improvement at follow-up on all SF-36 and FSS scores. Conclusions: The effects of combination therapy on HRQOL and fatigue are less with peginterferon alfa-2a plus ribavirin than interferon alfa-2b plus ribavirin. Each medication in combination therapy with interferon and ribavirin, affects patients' quality of life differently. Understanding the relationship of specific therapeutic options to HRQOL may help physicians minimize the impact of therapy on HRQOL. (C) 2004 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.